Press Releases

VANCOUVER, British Columbia and CAMBRIDGE, Mass. , June 12, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the presentation of data by researchers

VANCOUVER, British Columbia and CAMBRIDGE, Mass. , June 01, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the appointment of John J.

Global Expansion Plans for Metreleptin Opportunity to be Announced this Summer Defined Clinical Development Plan for Zuretinol Following Positive FDA Meeting Company Reiterates FY 2017 Total Net Revenues Guidance Between $155 and $165 million Conference call to be held today at 8:30 a.m.

VANCOUVER, British Columbia and CAMBRIDGE, Mass. , May 05, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the presentation of data by

VANCOUVER, British Columbia , April 25, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics, Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, announced today that the company will participate in the Bloom

VANCOUVER, British Columbia , April 19, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics, Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that, as part of its cost rationalization

VANCOUVER, British Columbia , March 31, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the appointment of Mark Corrigan , M.D.

VANCOUVER, British Columbia , March 31, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced its observance of World Lipodystrophy Day.